4 completed, 1 recruiting, 1 terminated, 1 unknown. 5 Phase 1, 3 Phase 2, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow tinostamustine: new trials by email Literature Review of tinostamustine trials Research Report on tinostamustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Tinostamustine for Adjuvant Treatment of Glioblastoma Tinostamustine - Glioblastoma Multiforme | Early Phase 1 | Completed | Mundipharma Research Limited | 10 | 2022-07-01 | 2025-12-10 |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma Temozolomide, Lomustine, Regorafenib - Glioblastoma | Phase 2 / Phase 3 | Recruiting | Global Coalition for Adaptive Research | 2250 | 2019-07-30 | 2026-10-23 |
| Tinostamustine and Nivolumab in Advanced Melanoma Tinostamustine - Malignant Melanoma | Phase 1 | Unknown | Markus Joerger | 21 | 2019-03-07 | 2019-04-08 |
| Tinostamustine Conditioning and Autologous Stem Cell Tinostamustine, Autologous Stem Cell Transplant (ASCT) - Multiple Myeloma in Relapse, Multiple Myeloma Progression | Phase 1 / Phase 2 | Terminated | Mundipharma-EDO GmbH | 6 | 2018-10-15 | 2021-06-18 |
| Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma Radiation Therapy, Tinostamustine - Glioblastoma, Gliosarcoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 5 | 2018-08-13 | 2025-06-04 |
| Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors. Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min - Small Cell Lung Cancer, Soft Tissue Sarcoma | Phase 1 / Phase 2 | Completed | Mundipharma Research Limited | 71 | 2017-11-08 | 2024-10-21 |
| Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Tinostamustine - Hematological Malignancies, Multiple Myeloma | Phase 1 | Completed | Mundipharma Research Limited | 106 | 2016-04-14 | 2024-07-25 |
Glioblastoma (3) · Recurrence (2) · Breast Neoplasms (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Gastrointestinal Stromal Tumors (1) · Gliosarcoma (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Lymphoma, T-Cell, Cutaneous (1) · Melanoma (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Sarcoma (1)
Mundipharma Research Limited (3) · Global Coalition for Adaptive Research (1) · M.D. Anderson Cancer Center (1) · Markus Joerger (1) · Mundipharma-EDO GmbH (1)
Switzerland (5) · United States (5) · Spain (3) · Canada (2) · France (2) · Germany (2) · Italy (2) · Netherlands (2) · Australia (1) · Norway (1)
Ana Oaknin, MD (1) · Dagmar Hess (1) · Markus Joerger, Prof. (1) · Parameswaran Hari, MD (1) · Pier L Zinzani, MD,PhD (1) · Shiao-Pei S Weathers (1) · Shivaani Kummar, MD (1) · Tim Cloughesy, MD (1) · Tomas Janik, MD (1)
PMID 38773224, PMID 39617826, PMID 41980234
2018 (1)